Acute and Sub-Acute Toxicity Study of Compound Siddha Drug Lagu Seena Chooranam for the Management of Scabies

A.Silambarasan[1]*, S.Gandhimathi[2], V.Rani[3]

1*. P.G.Scholar, Department of Paediatrics, Govt. Siddha Medical College, Chennai.

2. Asst. Lecturer, Department of Paediatrics, Govt. Siddha Medical College, Chennai.

3. HOD, Department of Paediatrics, Govt. Siddha Medical College, Chennai., India.

HUMAN JOURNALS

www.ijppr.humanjournals.com

ABSTRACT

Herbals are playing the major role in Siddha system of medicine. Herbals contain plant materials as their pharmacologically active components. Aim of the study is to evaluate the acute and sub-acute toxicity of the Siddha herbal preparation Lagu Seena Chooranam (LSC) for the treatment of Scabies in pediatric age group. For acute studies, different doses of LSC were administered orally to rats once daily for one week. Forsub-acute studies, different doses were administered orally to rats once daily for 28 days in various doses at 200, 400 mg/kg of body weight. Detailed hematological, biochemical, necropsy and Histopathological evaluation of organs was performed for all animals. Histopathological analysis revealed that Spleen, Testes, Pancreas, Lung, Liver, Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues of treated groups did not show any signs of toxicity. No destruction in hepatic, renal, haemopoietic functions were observed throughout the study.

INTRODUCTION

Plants are using for medicinal purpose since the ancient days. These medicinal plants are described as herbals. Herbals contain plant materials as their pharmacologically active components. These are playing the major role in Siddha system of medicine. Siddha system is the one of the popular traditional medicinal system in India. Traditional medicinal resources, especially plants have been found to play a major part in managing skin disorders [1]. Plants are the only economical source of a number of well-established and important drugs. In addition, they are also the source of chemical intermediates needs for the production of some drugs [2]. However, many issues related to a lack of scientific evidence about the efficacy and safety of herbal remedies remains unresolved [3, 4].

Pre-clinical toxicity studies are essential to determine a safe dose for human trial [5]. Prior to the initiation of human clinical trials of novel drugs, the safety of their application is to be proved. Generally this is accomplished by the implementation of general preclinical toxicity experiments to uncover potential poisonous effects of any drug in animals [6].

The present study was conducted to evaluate the acute and sub-acute toxicity of the siddha drug "Lagu Seena Chooranam (LSC)". The interventional drug "Lagu Seena Chooranam" has been quoted by *Agasthiar Vaithiya Pillai Thamizh* [7]. The drug is chosen for the treatment of Sirangu (Scabies) for the pediatric age group. This report aims to provide vital information about the efficacy and safety of the siddha drug Lagu Seena Chooranam.

MATERIALS AND METHODS

SOP of Lagu Seena Chooranam

Paranki pattai (*Smilax china*), Shivanar vembu verpattai (*Indigofera aspalathoides*), Sirukurinjan verpattai (*Gymnema sylvestre*), Thalaisuruli verpattai (*Aristolochia indica*), Sangankuppi ilai (*Clerodendrom inerme*), Sangan verpattai (*Azima tetracantha*), Vellarugu samoolam (*Enicostemma axillare*), Kaiyanthagarai samoolam (*Eclipta prostrate*), Sengathari verpattai (*Capparis sepiaria*). Above mentioned plants were taken in equal quantity. They were dried, purified and made into fine powder [7].

Species

Male and female Wistar rats of age 6 – 8 weeks old.

Citation: A.Silambarasan et al. Ijppr.Human, 2015; Vol. 4 (2): 358-370.

359

Environmental Conditions

Air conditioned rooms; temperature was between $22 \pm 2°C$ and illumination cycle set to 12 hours light and 12 hours dark.

Accommodation

Standard polypropylene rat cages with stainless steel top grill cleaned paddy husk were used as the bedding material. Animals were housed in groups of three animals of similar sex.

Sanitation

Bedding material and water bottles were changed daily.

Diet and water

Standard pellet feed was provided. Potable water passed through *ad libitum* in rat feeding bottles with stainless steel sipper tubes [8].

Acute toxicity study in rats [9]

Procedure

Acute toxicity study was carried out as per OECD guideline (Organization for Economic Co-operation and Development) 423. Healthy female rats weighing 220–240 gm were used for this study. Study carried out on female rats divided into two groups of 3 animals each under fasting condition (16 hrs prior to test animals deprived of food not for water), signs of toxicity was observed for every one hour for first 24 hours and everyday for about 14 days from the beginning of the study. All animals were observed daily for clinical signs. The time of onset, intensity and duration of these symptoms, if any, were recorded.

Observation

Animals were observed for possible signs of toxicity related to CNS, ANS and CVS.

Acute toxicity study grouping

Group I: Control Group: 3 female rats

Group II: Treatment group: 3 female rats

Dose: 2000 mg/kg

Route: Oral route (Single dose administration)

Citation: A.Silambarasan et al. Ijppr.Human, 2015; Vol. 4 (2): 358-370.

360

Sub-acute toxicity study in rats [10]

Procedure

Sub-acute toxicity study was carried out as per OECD guideline (Organization for Economic Co-operation and Development, Guideline-407. Animals were allowed acclimatization period of 7 days to laboratory conditions prior to the initiation of treatment. Three rats of same sex were housed per cage. Eighteen rats (09 male and 09 female healthy animals) were randomly divided into three groups of 6 animals.

Treatment groups were given daily dose for the period of 28 days. Control group animal left untreated, Animal belongs to group II treated with low dose of the test drug 200 mg/kg and Group III treated with high dose of the test drug 400 mg/kg oral by gastric intubation technique. All animals were observed daily for clinical signs of toxicity. The time of onset, intensity and duration of the symptoms, if any, were recorded. Body weight, food intake, water intake and other general behavior of the animals will be monitored and recorded once in a week for the entire duration of the study.

Sub-acute toxicity study grouping

Group I: Control Group: 6 rats (3 male and 3 female)

Group II: Treatment group: 6 rats (3 male and 3 female) - Low dose 200 mg/kg

Group III: Treatment group: 6 rats (3 male and 3 female) - High dose 400 mg/kg

Dose: Low dose 200 mg/kg and high dose 400 mg/kg

Route: Oral route (repeated dose administration)

Haematological and Biochemical Investigations [11]

Blood was collected through retro-orbital sinus from all the animals of different groups on 29th day. The blood was collected in tubes containing Heparin/EDTA as an anticoagulant. Animals were fasted overnight prior to the blood collection. Haematological and biochemical parameters were determined using Auto analyzer using standard kits and the data are provided.

Necropsy

All animals were sacrificed by cervical dislocation on 29th day. Necropsy of all animals were carried out and the weights of the vital organs were recorded (heart, liver, kidneys and brain).

Citation: A.Silambarasan et al. Ijppr.Human, 2015; Vol. 4 (2): 358-370.

361

Histopathology

During necropsy the target organs viz., heart, liver, kidneys and brain were collected and preserved in 10 % neutral formalin buffer for the histopathological evaluation. The organs from control and treated animals were preserved in 10 % neutral formalin buffer for histopathological examination.

RESULTS AND DISCUSSION

Acute toxicity study

Acute toxicity effect of the test drug was estimated by close observation of animals for about 24 hours after single dose administration of the test drug and it was observed that there is no significant signs of CNS related toxicity like convulsion, locomotion, muscle strength and ANS related toxicity like salivation, lacrimation etc. was observed in treatment group. At the end of the study period all animals were sacrificed and the organs was isolated and observed for change in structural morphology. There is no significant change in the organ necropsy of the animals treated with the test drug. It shows that the test drug did not produce any internal hemorrhage or organ related toxicity.

Table 1: Parameter checked

Group	Day
Body weight	Normal
Assessments of posture	Normal
Signs of Convulsion:Limb paralysis	Absence of sign (-)
Body tone	Normal
Lacrimation	Absence
Salivation	Very mild
Change in skin color	No significant color change
Piloerection	Not observed
Defecation	Regular Solid consistency
Sensitivity response	Normal
Locomotion	Normal
Muscle grip	Normal
Rearing	Normal
Urination/Color	Slightly turbid

Citation: A.Silambarasan et al. Ijppr.Human, 2015; Vol. 4 (2): 358-370.

362

Table 2: Effect of Test drug on Mortality rate of the study animals on Acute toxicity study

Treatment	Mortality observed for the duration of 1- 14 days
Group I - Control	NIL
Group II- Treatment	NIL

Sub - Acute toxicity study

Sub-acute toxicity for the given test drug was carried out as per the OECD guideline 407 by repeated dose administration of the test drug in animals and further animals were closely monitored for the emergence of toxicity. Since, there were no significant adverse effects on the hematological, biochemical and histopathological parameters it may be concluded that the test drug at both the dose level of 200 mg/kg and 400 mg/kg may be considered as relatively safe, as it did not cause either mortality or produce severe toxicological effects on selected body organs, biochemical indices, hematological and histopathological markers of rats during the sub-acute periods of study (Figure 1).

Table 3: Effect of Test drug on Mortality rate of the study animals on Sub-Acute toxicity study

Treatment	Mortality observed for the duration of 1- 28 days
Group I - Control	NIL
Group II- Low Dose	NIL
Group III- High Dose	NIL

Citation: A.Silambarasan et al. Ijppr.Human, 2015; Vol. 4 (2): 358-370.

363

Table 4: Effect of test drug on Body weight and Food consumption

Control	Food (g/day/rat)	Body weight (g)
Mean	24.67	234.5
Std. Deviation	2.422	2.429
Std. Error	0.9888	0.9916
Low Dose	**Food (g/day/rat)**	**Body weight (g)**
Mean	23.67	234
Std. Deviation	3.386	2
Std. Error	1.382	0.8165
High Dose	**Food (g/day/rat)**	**Body weight (g)**
Mean	22.17	232.7
Std. Deviation	1.472	2.805
Std. Error	0.6009	1.145

Citation: A.Silambarasan et al. Ijppr.Human, 2015; Vol. 4 (2): 358-370.

364

Table 5: Effect of test drug on Hematological and Biochemical analysis

Control	Total red cells count ($\times 10^6$ μl)	Total WBC count ($\times 10^3$ μl)	Platelet count ($\times 10^3$ μl)	Packed cell volume (%)	MCV (fl)	MCH (pg)	MCHC (g/dl)	Blood sugar ® (mg/dl)	BUN (mg/dl)
Mean	6.667	9.333	546.3	56	62.67	31.67	50	88.17	19.5
Std. Deviation	1.506	2.733	41.52	9.529	5.785	4.412	2.28	5.707	2.881
Std. Error	0.6146	1.116	16.95	3.89	2.362	1.801	0.9309	2.33	1.176
Low Dose	**Total red cells count ($\times 10^6$ μl)**	**Total WBC count ($\times 10^3$ μl)**	**Platelet count ($\times 10^3$ μl)**	**Packed cell volume (%)**	**MCV (fl)**	**MCH (pg)**	**MCHC (g/dl)**	**Blood sugar ® (mg/dl)**	**BUN (mg/dl)**
Mean	7.667	9.167	584.8	49.17	57.5	29.33	44.67	71.83	14.17
Std. Deviation	0.5164	0.4082	20.42	2.714	4.68	5.715	1.633	1.602	2.994
Std. Error	0.2108	0.1667	8.336	1.108	1.91	2.333	0.6667	0.654	1.222
High Dose	**Total red cells count ($\times 10^6$ μl)**	**Total WBC count ($\times 10^3$ μl)**	**Platelet count ($\times 10^3$ μl)**	**Packed cell volume (%)**	**MCV (fl)**	**MCH (pg)**	**MCHC (g/dl)**	**Blood sugar ® (mg/dl)**	**BUN (mg/dl)**
Mean	6	9.5	502.7	55.17	61.33	31.67	41.33	83.33	20.33
Std. Deviation	1.095	1.975	15.45	1.602	5.086	3.141	5.785	3.724	3.141
Std. Error	0.4472	0.8062	6.307	0.654	2.076	1.282	2.362	1.52	1.282

Citation: A.Silambarasan et al. Ijppr.Human, 2015; Vol. 4 (2): 358-370.

365

Table 6: Effect of test drug on Serum creatinine and lipid profile

Control	Serum creatinine (mg/dl)	Serum total cholesterol (mg/dl)	Serum triglycerides level (mg/dl)	Serum HDL cholesterol (mg/dl)	Serum LDL cholesterol (mg/dl)	Serum VLDL cholesterol (mg/dl)	Serum total protein (g/dl)
Mean	0.7333	104.3	45	23.5	54.83	40.67	6.3
Std. Deviation	0.1506	7.394	2.098	1.871	3.371	3.386	2.825
Std. Error	0.06146	3.018	0.8563	0.7638	1.376	1.382	1.153
Low Dose	Serum creatinine (mg/dl)	Serum total cholesterol (mg/dl)	Serum triglycerides level (mg/dl)	Serum HDL cholesterol (mg/dl)	Serum LDL cholesterol (mg/dl)	Serum VLDL cholesterol (mg/dl)	Serum total protein (g/dl)
Mean	1.033	102.8	49.33	20.67	51.33	36.33	5.517
Std. Deviation	0.1862	6.853	5.428	2.875	2.338	3.777	0.5115
Std. Error	0.07601	2.798	2.216	1.174	0.9545	1.542	0.2088
High Dose	Serum creatinine (mg/dl)	Serum total cholesterol (mg/dl)	Serum triglycerides level (mg/dl)	Serum HDL cholesterol (mg/dl)	Serum LDL cholesterol (mg/dl)	Serum VLDL cholesterol (mg/dl)	Serum total protein (g/dl)
Mean	1.133	104.3	54.17	25.17	55.83	39	5.333
Std. Deviation	0.1862	2.805	1.835	2.317	2.041	2.966	1.506
Std. Error	0.07601	1.145	0.7491	0.9458	0.8333	1.211	0.6146

Citation: A.Silambarasan et al. Ijppr.Human, 2015; Vol. 4 (2): 358-370.

366

Table 7: Effect of test drug on Albumin and Liver enzymes analysis

Control	Serum albumin (g/dl)	SGOT (AST) (IU/ml)	SGPT (ALT) (IU/L)
Mean	4.7	126.2	65.67
Std. Deviation	1.934	4.401	3.077
Std. Error	0.7895	1.797	1.256
Low Dose	Serum albumin (g/dl)	SGOT (AST) (IU/ml)	SGPT (ALT) (IU/L)
Mean	3.083	147.2	74.67
Std. Deviation	0.343	9.867	1.506
Std. Error	0.14	4.028	0.6146
High Dose	Serum albumin (g/dl)	SGOT (AST) (IU/ml)	SGPT (ALT) (IU/L)
Mean	4.667	116.2	70
Std. Deviation	0.5164	1.835	6.753
Std. Error	0.2108	0.7491	2.757

Citation: A.Silambarasan et al. Ijppr.Human, 2015; Vol. 4 (2): 358-370.

367

Table 8: Effect of test drug on Blood cell count

Control	HB (g/dl)	neutrophils (%)	lymphocytes (%)	eosinophils (%)	monocytes (%)	basophils (%)
Mean	15.5	75.17	36.5	1.85	0.6667	0.5
Std. Deviation	1.761	2.927	3.391	0.3782	0.2066	0.5477
Std. Error	0.7188	1.195	1.384	0.1544	0.08433	0.2236
Low Dose	HB (g/dl)	neutrophils (%)	lymphocytes (%)	eosinophils (%)	monocytes (%)	basophils (%)
Mean	16.67	76.5	34.83	1.483	0.9333	0.1667
Std. Deviation	1.211	1.643	2.317	0.3189	0.1033	0.4082
Std. Error	0.4944	0.6708	0.9458	0.1302	0.04216	0.1667
High Dose	HB (g/dl)	neutrophils (%)	lymphocytes (%)	eosinophils (%)	monocytes (%)	basophils (%)
Mean	15.5	73.5	36.17	1.333	0.5667	0.3333
Std. Deviation	0.5477	2.881	6.08	0.2422	0.1966	0.5164
Std. Error	0.2236	1.176	2.482	0.09888	0.08028	0.2108

Table 9: Effect of test drug on organ morphology

Grouping	Kidney	Liver	Heart	Lungs	Spleen	Pancreas	Brain	Ovaries	Testes
Group I – Control	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal
Group II- Low Dose	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal
Group III- High Dose	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal	Normal

*Citation: A.Silambarasan et al. Ijppr.Human, 2015; Vol. 4 (2): 358-370.*

368

Figure 1

CONCLUSION

The present exploration demonstrates that the doses consumed in the traditional medicine, i.e. LSC may be considered as relatively safe, as it does not cause either mortality or produce severe toxicological effects on selected body organs, biochemical incite and hematological markers of rats during the acute and sub-acute periods of study.

REFERENCES

1. Abbasi AM, Khan MA, Ahmad M, Zafar M, Jahan S, Sultana S: Ethnopharmacological application of medicinal plants to cure skin diseases and in folk cosmetics among the tribal communities of North-West Frontier Province, Pakistan. J Ethnopharmacol 2010,128:322–335.

2. K. Samraj, S. Thillaivanan, and P. Parthiban: A review of beneficial effects of medicinal plants on skin and skinDiseases; IJPRBS, 2014; Volume 3(1): 93-106

Citation: A.Silambarasan et al. Ijppr.Human, 2015; Vol. 4 (2): 358-370.

369

3. Shekelle PG, Morton SC, Suttorp MJ, Buscemi N, Friesen C, Challenges in systematic reviews of complementary and alternative medicine topics. Ann Intern Med 2005; 142: 1042-1047

4. Rahul B. Patil, Shreya R. Vora and Meena M. Pillai, Protective effect of Spermatogenic activity of Withaniasomnifera (Ashwagandha) in galactose stressed mice, Annals of Biological Research, 2012; 3(8):4159-4165. (http://scholarsresearchlibrary.com/archive.html).

5. Anoop A,Jagadeesan M &Subramanium S, Toxicological studies on *LingaChendooram*-I, a siddha drug , Indian J PharmaSci 64 (1) (2002) 53

6. Farzamfar B et al (2008), Sub-chronic toxicity study of a novel herbal-based formulation (Semelil) on dogs, DARU Vol. 16, Suppl. 1 2008, (http://journals.tums.ac.ir/ on Friday, May 24, 2013).

7. Anonymous, Agasthiyar Vaithiya Pillai Thamizh, , Thamarainoolagam, Vadapalani, Chennai, 1999;72

8. Benjamin, M.N., 1978.Outline of Veterinary Clinical Pathology. University Press, IOWA, USA. pp: 229-232.

9. Organization for Economic Cooperation Development (OECD) Guideline, 425, 2000. Guideline Document on Acute Oral Toxicity. Environmental Health and Safety Monograph Series on Testing and Assessment No. 24.

10.OECD (testing guideline, 407), 1995. Repeat dose 28 days oral toxicity study in rodents; In Guidance document for the development of OECD guideline for testing of chemicals Environmental monographs No 76; http//www.oecd.ord/document/30/0.2340,en??2649-34377-19166381111, 00html.

11.Ringler, D.H. and L. Dabich, 1979. Haematology and Clinical Biochemistry. In: The Laboratory Rat. Baker, J., J.R. Lindsey and S.H. Weisbroth (Eds.), Academic Press London, 1: 105-118.

Citation: A.Silambarasan et al. Ijppr.Human, 2015; Vol. 4 (2): 358-370.

370